Ensysce Biosciences Inc ENSC

$0.40 0.00 (-1.20%)

Valuation

Market cap
7,779,000
Revenue TTM
$5,070,000
Net income TTM
$-10,180,000
PE ratio
0.00
Forward PE
—
Profit margin
-200.79%
Debt to equity
0.00

Trading

Volume
173,900
Avg volume
17,685,381
Day's range
$0.39 – $0.43
Shares out
19,457,000
Stochastic %K
4%
Beta
1.00
Analysts
Strong Buy
Price target
$8.25

Price

Company profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-do...

Show more

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 263 4196
Website
https://www.ensysce.com
Address
7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

Latest news

Stocktwits

Bernic88 Oct 2, 8:06 PM
$ENSC There’s always a slight pre-market rise to lure in new investors. Then comes the rude awakening—slipping a little lower every day. Management couldn't care less about its investors.
0 replies
BULLISH1975 Oct 2, 6:39 PM
$ENSC keep eyes on $ICU my biggest holding—- way undervalued! started to move. bullion dollar MC potential within 12 months if adult phase III approved mud 2027. same SCD device already pediatric FDA HDE approved- results undeniable dyor
0 replies
Bernic88 Oct 2, 5:23 PM
$ENSC Not another word about the PF614-301 Phase 3 trial, yet constant talk and hype surrounding the new CY200. Are the data not good, or what’s going on?
0 replies
Bernic88 Oct 2, 5:19 PM
$ENSC when .25?
0 replies
StockDreamin Oct 2, 5:03 PM
$ENSC fukn joke
0 replies
Bernic88 Oct 2, 3:49 PM
$ENSC
0 replies
Sunnybhargava Oct 2, 2:10 PM
$ENSC Data management want to keep secret. But for how long. Don’t act too abnormal .its been too long.
0 replies
Bernic88 Oct 2, 2:03 PM
$ENSC There’s no trace left of the Saudi Arabian pumpers on X, either. I think they’ve realized they can’t manage to pump that crap to .49
0 replies